Our findings demonstrate that Nanoligomers specifically formulated to target NF-κB and NLRP3 are safe and well-tolerated, engage their target proteins in the brain, reduce neuroinflammation and improve cognitive function with both aging and tauopathy. The gene discussed is NFKB1; the disease is tauopathy.